Key result
A panel of candidate polymorphisms showed no association with post-angioplasty restenosis, highlighting the need for much larger studies to identify causal genetic variation.
Why the study?
Genetic risk markers for restenosis after angioplasty have potential to improve understanding of causal factors and aid development of novel therapies, but evidence is limited.
Candidate polymorphisms should not inform restenosis risk stratification; leaves open broader genetic contributions to post-PCI outcomes.
Genetic risk markers for coronary artery disease and associated phenotypes, such as restenosis after angioplasty, have the potential to be valuable to the individual, but even more so in facilitating an understanding of causal factors in the disease, and thereby the development of novel preventative and therapeutic strategies. In this issue of Clinical Science, Völzke and co-workers were unable to show association of a panel of candidate polymorphisms with restenosis, but their study has highlighted the need for even larger studies, as well as the potential benefits of finding causal genetic variation.
No takes yet. Share an insight, caveat, or question.
Fiona R. Green (2004) conducted an editorial in post-angioplasty restenosis. Candidate polymorphisms was evaluated on post-angioplasty restenosis. A panel of candidate polymorphisms showed no association with post-angioplasty restenosis, highlighting the need for much larger studies to identify causal genetic variation.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: